The life science investment arm of a global private equity firm with multi-billion dollars in assets under management has offices across the USA. The fund may invest a total of up to $20 million per portfolio company across multiple financing rounds, and may be a lead investor or a co-investor. The firm is interested in life science opportunities worldwide. The PE firm also has a separate investment arm that invests in early growth companies in the medical device, healthcare IT and diagnostics sectors.
The firm invests in therapeutics, medical devices and diagnostics. For therapeutic investments, the fund generally looks for clinical proof of efficacy in Phase Ib or IIa trials. For PMA medical devices, the firm also requires clinical proof of efficacy data. For 510k devices and diagnostics, the firm makes growth equity investments in companies that have approved products and are in early commercialization. It is required that diagnostics have reimbursement codes. The firm will consider investments in any indication or technology area.
The growth-stage investment arm invests in digital health, medtech and diagnostics companies with revenue streams, and uses a variety of structures to provide credit or royalty financing to early growth stage companies.
The firm invests in both experienced management teams, as well as new entrepreneurs. The firm is open to investing in both privately-held and public companies. If a management team is incomplete or inexperienced, The firm is open to working to fill or change the team.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply